KMT2A and acute myeloid leukemia: In order to validate MLL-AF9 binding to the ZNF521 promoter in AML cells, we performed ChIP with lysate from NOMO-1 and HL60 cell lines that endogenously expressing MLL-AF9 and WT MLL, respectively.